Learning archive

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
  • December 9, 2024

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

On Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies (DLB). The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (a measure of dementia severity) or any of its key secondary endpoints – change from baseline in Timed Up and Go (measures a person’s mobility, balance, a

Read More
Wall Street Advisers Say Dealmaking Will Pick Up in Trump Era
  • December 9, 2024

Wall Street Advisers Say Dealmaking Will Pick Up in Trump Era

(Bloomberg) -- Companies are dusting off their dealmaking playbooks as an expected loosening of regulation lifts both acquisitions and stock market debuts in the coming year, according to Wall Street advisers.Most Read from BloombergBrace for a Nationwide Shuffle of Corporate HeadquartersCloud Computing Tax Threatens Chicago’s Silicon Valley DreamA Chicago Skyscraper Cements the Legacy of a Visionary Postmodern ArchitectSan Francisco, Paris Named Best Cities for Urban TransportationDC Business L

Read More
Super Micro CEO confident stock will not be delisted
  • December 9, 2024

Super Micro CEO confident stock will not be delisted

NEW YORK (Reuters) -Super Micro Computer Chief Executive Charles Liang on Tuesday said he is confident the technology company's stock will not be delisted from the Nasdaq. On the sidelines of the Reuters NEXT conference in New York, Liang said Super Micro would file its necessary financial reports by February. The embattled company received a letter last week from Nasdaq that gave it a deadline of Feb. 25 to file its delayed annual and quarterly reports, in an exception to the stock exchange's rules.

Read More
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?
  • December 9, 2024

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

On Tuesday, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. ASCVD is a chronic disease that occurs when plaque builds up in the walls of arteries, narrowing them and reducing blood flo

Read More
Muni Managers Launch Record ETFs to Build on $142 Billion Market
  • December 9, 2024

Muni Managers Launch Record ETFs to Build on $142 Billion Market

(Bloomberg) -- Wall Street’s biggest money managers are zeroing in on a $142 billion segment of the municipal-bond market.Most Read from BloombergBrace for a Nationwide Shuffle of Corporate HeadquartersCloud Computing Tax Threatens Chicago’s Silicon Valley DreamA Chicago Skyscraper Cements the Legacy of a Visionary Postmodern ArchitectSan Francisco, Paris Named Best Cities for Urban TransportationDC Business Leaders Welcome Return-to-Office Policy Under TrumpThere have been 27 muni exchange-trad

Read More